United States - English - NLM (National Library of Medicine)

teva women's health llc - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - quartette®  is indicated for use by females of reproductive age to prevent pregnancy. quartette is contraindicated in females who are known to have or develop the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include females who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)]. have current or history of deep vein thrombosis or pulmonary embolism [see warnings and precautions (5.1)]. have cerebrovascular disease [see warnings and precautions (5.1)]. have coronary artery disease [see warnings and precautions (5.1)]. have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1)]. have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1)].   have uncontrolled hypertension or hypertension with vascular disease [see warnings and precautions (5.5)]. have di

United States - English - NLM (National Library of Medicine)

xiromed, llc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.1 mg - lojaimiess® is indicated for use by females of reproductive potential to prevent pregnancy. lojaimiess is contraindicated in females who are known to have or develop the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include females who are known to: smoke, if over age 35[see boxed warning and warnings and precautions (5.1)] have current or history of deep vein thrombosis or pulmonary embolism [see warnings and precautions (5.1)] have cerebrovascular disease [see warnings and precautions (5.1)] have coronary artery disease [see warnings and precautions (5.1)] have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1 )] have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1 )] have uncontrolled hypertension or hypertension with vascular disease [see warnings and precautions (5.5)] ha

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.1 mg - camrese lo® is indicated for use by females of reproductive potential to prevent pregnancy. camrese lo is contraindicated in females who are known to have or develop the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include females who are known to:  smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] have current or history of deep vein thrombosis or pulmonary embolism [see warnings and precautions (5.1 )] have cerebrovascular disease [see warnings and precautions (5.1 )] have coronary artery disease [see warnings and precautions (5.1 )] have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1 )] have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1 )] have uncontrolled hypertension or hypertension with vascular disease [see warnings and precautions (5.5)] ha

United States - English - NLM (National Library of Medicine)

teva women's health llc - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.1 mg - loseasonique® is indicated for use by females of reproductive potential to prevent pregnancy. loseasonique is contraindicated in females who are known to have or develop the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include females who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] have current or history of deep vein thrombosis or pulmonary embolism [see warnings and precautions (5.1)] have cerebrovascular disease [see warnings and precautions (5.1)] have coronary artery disease [see warnings and precautions (5.1)] have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1 )] have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1 )] have uncontrolled hypertension or hypertension with vascular disease [see warnings and precautions (5.5)]

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - camrese®  is indicated for use by females of reproductive potential to prevent pregnancy. camrese is contraindicated in females who are known to have or develop the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include females who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)]. have current or history of deep vein thrombosis or pulmonary embolism [see warnings and precautions (5.1 )]. have cerebrovascular disease [see warnings and precautions (5.1 )] have coronary artery disease [see warnings and precautions (5.1 )]. have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1 )]. have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1 )]. have uncontrolled hypertension or hypertension with vascular disease [see warnings and precautions (5.3)]. hav

United States - English - NLM (National Library of Medicine)

teva women's health llc - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - seasonique® is indicated for use by females of reproductive potential to prevent pregnancy. seasonique is contraindicated in females who are known to have or develop the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include females who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)]. have current or history of deep vein thrombosis or pulmonary embolism [see warnings and precautions (5.1)]. have cerebrovascular disease [see warnings and precautions (5.1)] have coronary artery disease [see warnings and precautions (5.1)]. have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1)]. have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1)]. have uncontrolled hypertension or hypertension with vascular disease [see warnings and precautions ( 5.3 )].

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel and ethinyl estradiol tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table 2 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and norplant ® system, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. table 2: percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of contraception and the percentage continuing use at the end of the first year. united states. emergency contraceptive pills: the fda has concluded that certain combined oral contraceptives containing ethinyl estradiol and norgestrel or levonorgestrel are safe and effective for use as p

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - jolessa™ tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. in a 1-year controlled clinical trial, 4 pregnancies occurred in women 18-35 years of age during 809 completed 91-day cycles of jolessa™ during which no backup contraception was utilized. this represents an overall use-efficacy (typical user efficacy) pregnancy rate of 1.98 per 100 women-years of use. oral contraceptives are highly effective for pregnancy prevention. table 2 lists the typical unintended pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and norplant® implant system, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. oral contraceptives should not be used in women who currently have the following conditions: - thrombophlebitis or thromboembolic dis

United States - English - NLM (National Library of Medicine)

mayne pharma inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - levora 0.15/30-28 is indicated for use by females of reproductive potential to prevent pregnancy. levora 0.15/30-28 is contraindicated in females who are known to have the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: – smoke, if over age 35 [see boxed warning and warnings (1)]. – have current or history of deep vein thrombosis or pulmonary embolism [see warnings (1)]. – have cerebrovascular disease [see warnings (1)]. – have coronary artery disease [see warnings (1)]. – have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings (1)]. – have inherited or acquired hypercoagulopathies [see warnings (1)]. – have uncontrolled hypertension or hypertension with vascular disease [see warnings (4)]. – have diabetes mellitus and are over age 35, diabetes mellitus with hypertension or vascular disease or other end-or

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - ayuna is indicated for use by females of reproductive potential to prevent pregnancy. ayuna is contraindicated in females who are known to have the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are  known to: smoke, if over age 35 [see boxed warning and warnings (1)]. have current or history of deep vein thrombosis or pulmonary embolism [see warnings (1)].  have cerebrovascular disease [see warnings (1)]. have coronary artery disease [see warnings (1)]. have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings (1)]. have inherited or acquired hypercoagulopathies [see warnings (1)]. have uncontrolled hypertension or hypertension with vascular disease [see warnings (3)]. have diabetes mellitus and are over age 35, diabetes mellitus with hypertension or vascular disease or other end-organ damage, or diabetes mellitus of >2